金麦安博生物制药

Beijing Jinmai Anbo Biopharmaceutical is a Chinese biotechnology company focused on the research, development, and manufacturing of innovative recombinant protein therapeutics. Established in 2021 and headquartered in the Beijing Daxing Bio-Medicine Industry Park, the company leverages proprietary high-expression cell line platforms to develop complex biologics with optimized pharmacological profiles. Its lead program, JM-001, is a recombinant human hyaluronidase (rHuPH20) designed to facilitate the subcutaneous administration of large-volume biologics, thereby improving patient convenience and treatment efficiency. The company maintains integrated capabilities spanning from early-stage molecular design to pilot-scale GMP manufacturing. Jinmai Anbo aims to address significant unmet needs in drug delivery and metabolic diseases through its specialized protein engineering expertise.